Psychedelic Science Newsletter
Issue #20January 19, 20267 studies

Psilocybin trials show glaring blind spots, while low-dose LSD changes reward processing in depressed brains

Psychedelic research is hitting some growing pains. While hundreds of studies are underway, regulatory hurdles are mounting and researchers are discovering that the devil is in the details they're not reporting.

๐Ÿ„ Psilocybin trials are missing the forest for the trees

Researchers evaluated 13 psilocybin clinical trials for depression using new reporting guidelines and found some glaring blind spots:

  • Only 15.6% of required details about "set and setting" (the psychological and physical environment) were fully reported, despite these factors being crucial for psychedelic outcomes

  • While 100% of trials documented medical procedures and 92.3% described session activities, 84.6% failed to mention cultural competence measures and 92.3% didn't describe room decorations or objects

  • 84.6% of protocols provided no information about patient access to nature during treatment

Why it matters: These contextual details aren't just nice-to-havesโ€”they may directly influence whether psychedelic therapy works, yet most trials aren't systematically tracking them.

Key Findings

๐Ÿ’Š Ketamine dramatically reduces suicide thoughts in high-risk patients

A meta-analysis of 21 studies with 927 participants found ketamine's anti-suicidal effects are both rapid and substantial:

  • Large effect size of -1.40 for reducing suicidal thoughts, with benefits appearing strongest in younger patients and those with severe ideation

  • Most common side effects were dissociation (38.8%), nausea (31.6%), and dizziness (24.7%)

  • Effects were particularly pronounced in younger individuals and those with the most severe suicidal thoughts

๐Ÿ’ก Ketamine may offer a critical intervention for suicide prevention, especially when traditional antidepressants take weeks to work.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Epidemiology and psychiatric sciences Systematic Review ๐Ÿ—“๏ธ Jan 12

๐Ÿง  Low-dose LSD changes reward processing in depressed brains

Researchers gave 39 participants either 26 ฮผg of LSD or placebo and measured brain responses during a monetary reward task:

  • LSD increased brain responses to financial losses (vs wins) only in participants with higher baseline depression scores

  • This enhanced response to losses was linked to improved mood both immediately and 48 hours after the LSD session

  • The effect suggests LSD may help depressed brains process emotional information about rewards more effectively

๐Ÿ’ก Microdoses of LSD may work differently in depressed vs healthy brains, potentially explaining why some people report mood benefits.
๐ŸŽ–๏ธ Top 10% journal ๐Ÿ”— Journal of psychopharmacology (Oxford, England) Journal Article ๐Ÿ—“๏ธ Jan 13

๐Ÿš’ Firefighters face major barriers to ketamine therapy for PTSD

Interviews with six firefighters enrolled in a ketamine-assisted therapy program revealed systemic obstacles:

  • PTSD rates in firefighters average 7.3% compared to 1.3-3.5% in the general population

  • Major themes included feeling "stuck and reaching a breaking point," stigma around both PTSD and ketamine treatment, and substantial financial and logistical barriers

  • Self-advocacy was crucial for navigating access to treatment, suggesting the system isn't set up to support those who need it most

๐Ÿ’ก Even promising PTSD treatments may fail if the healthcare system can't deliver them to high-risk populations.
Top 30% journal ๐Ÿ”— Journal of Occupational and Environmental Medicine ๐Ÿ—“๏ธ Jan 15

๐Ÿ”ฌ Psychedelics boost specific brain waves linked to visual perception

Using brain imaging in awake mice, researchers found that psychedelic drugs specifically amplify 5-Hz brain oscillations:

  • 5-Hz oscillations occurred in both visual and retrosplenial cortex areas, both spontaneously and when triggered by visual stimulation

  • Psychedelic 5-HT2A receptor activation significantly increased the power, occurrence, and persistence of these oscillations

  • This pattern may explain how psychedelics create visual hallucinations through enhanced "top-down" brain control

๐Ÿ’ก The specific brain waves psychedelics enhance may reveal the neural basis of hallucinations and altered perception.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Communications biology Journal Article ๐Ÿ—“๏ธ Jan 12

โš ๏ธ Recreational ketamine withdrawal hits memory and brain chemistry hard

Adolescent female rats given recreational doses of ketamine (10 mg/kg for 3 days) showed broad cognitive impairments 24 hours after stopping:

  • All memory types testedโ€”episodic, social, and working memoryโ€”were significantly impaired during early withdrawal

  • Serotonin and norepinephrine levels dropped substantially in both the hippocampus and prefrontal cortex

  • The study mimicked weekend party use patterns, suggesting even short-term recreational use may have lasting effects

๐Ÿ’ก Even brief recreational ketamine use may disrupt multiple brain systems critical for memory and mood regulation.
Top 20% journal ๐Ÿ”— Behavioural brain research Journal Article ๐Ÿ—“๏ธ Jan 18

๐ŸŽฏ Psychedelics show promise for treatment-resistant depression

A systematic review of 15 studies found consistent benefits across different psychedelic compounds for the hardest-to-treat depression cases:

  • 10 randomized controlled trials and 5 open-label studies all showed efficacy for treatment-resistant depression

  • Benefits appeared across multiple classes of psychedelics, not just one specific compound

  • Results suggest psychedelics may work through different mechanisms than traditional antidepressants, offering hope for patients who don't respond to standard treatments

๐Ÿ’ก Multiple psychedelic compounds may offer new options for the roughly 30% of depression patients who don't respond to conventional treatments.
Top 30% journal ๐Ÿ”— Journal of clinical psychopharmacology Journal Article ๐Ÿ—“๏ธ Jan 12

Implications

The psychedelic therapy field is experiencing growing pains as it moves from promising early results toward mainstream medicine. While compounds like ketamine are showing robust effects for severe conditions like suicide risk, the research infrastructure still needs workโ€”from better reporting standards to addressing access barriers for those who need these treatments most.

Studies in this issue

Primary sources used for this newsletter.

  1. Using ReSPCT guidelines to improve reporting in psilocybin clinical trial plans
    main storyEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2026-01-17PMID 41546918
  2. Brain reward system activity after low doses of LSD in people with depressed mood
    key findingJournal of psychopharmacology (Oxford, England)2026-01-13PMID 41529826
  3. Possible Benefits of Psychedelics for Hard-to-Treat Depression: Fact or Fiction? A Review
    key findingJournal of clinical psychopharmacology2026-01-12PMID 41521955
  4. Challenges Firefighters Face Getting Ketamine Therapy for PTSD
    key findingJournal of Occupational and Environmental Medicine2026-01-16PMID 41540564
  5. Ketamine treatment may reduce suicidal thoughts in high-risk groups
    key findingEpidemiology and psychiatric sciences2026-01-12PMID 41521819